Physician profile
Nathan Smith
NPI 1174884662
$1,668.24
in general payments reported to CMS, 2019-2025
18 companies · $52.38 in 2025
The $52.38 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.97 · 2021: $328 · 2022: $847 · 2023: $386 · 2024: $19.82 · 2025: $52.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421 · Education: $36.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.46 |
| Education | $36.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $477.27 | 2021-2023 | Proclaim |
| Nevro Corp. | $353.18 | 2021-2022 | |
| Boston Scientific Corporation | $222.52 | 2021 | |
| Saluda Medical Americas, INC. | $192.84 | 2023 | Evoke Scs |
| Amgen INC. | $116.45 | 2021-2022 | |
| Lilly USA, LLC | $64.33 | 2023 | Emgality |
| Pfizer INC. | $34.57 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $31.51 | 2025 | Gemtesa |
| Abbvie INC. | $24.54 | 2023 | Qulipta |
| La Jolla Pharmaceutical Company | $21.16 | 2020 | |
| Forte Bio-Pharma LLC | $20.27 | 2023 | Prolate, Nalocet |
| Baudax Bio INC. | $19.96 | 2022 | |
| Mirum Pharmaceuticals, INC. | $19.82 | 2024 | Cholbam |
| Edwards Lifesciences Corporation | $17.35 | 2023 | Hemosphere |
| Redhill Biopharma INC. | $15.19 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.81 | 2020 | |
| Collegium Pharmaceutical, INC. | $12.48 | 2021 | |
| Stimwave Technologies Incorporated | $9.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.